ArticleJournal of experimental & clinical cancer research : CR2015
Dual loading miR-218 mimics and Temozolomide using AuCOOH@FA-CS drug delivery system: promising targeted anti-tumor drug delivery system with sequential release functions.
Article in Journal of experimental & clinical cancer research : CR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies.Frontiers in cell and developmental biology · 2024Review
- Carborane-Containing Folic AcidInternational journal of molecular sciences · 2022Article
- Article
- Inhibiting the Growth of 3D Brain Cancer Models with Bio-Coronated Liposomal Temozolomide.Pharmaceutics · 2021Article
- Therapeutic Targeting of MicroRNAs in the Tumor Microenvironment.International journal of molecular sciences · 2021Review
- Nanogel: A Versatile Nano-Delivery System for Biomedical Applications.Pharmaceutics · 2020Review
- Nanoscale delivery systems for microRNAs in cancer therapy.Cellular and molecular life sciences : CMLS · 2020Review
- Development of an Aryloxazole Derivative as a Brain-Permeable Anti-Glioblastoma Agent.Pharmaceutics · 2019Article
- Current promising treatment strategy for glioblastoma multiform: A review.Oncology reviews · 2019Article
- The protean world of non-coding RNAs in glioblastoma.Journal of molecular medicine (Berlin, Germany) · 2019Review
- Enhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics.Frontiers in pharmacology · 2019Review
- RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.Life sciences · 2017Review
- Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review).International journal of oncology · 2016Review
Corrections and comments
- Retraction · 2021-08-11Concerns/Issues about Data · Duplication of/in Image · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDual loading drug delivery system with tumor targeting efficacy and sequential release function provides a promising platform for anticancer drug delivery. Herein, we established a novel AuCOOH@FACS nanogel system for co-delivery miR-218 mimics (as bio-drug) and Temozolomide(as chemo-drug).
methodsDLS and TEM were employed to determine the characteristics of particles and nanogels. The cell viability was calculated for study synergistic effect of both drugs coadministration and in nanogel forms. The amounts of Au uptake were measured by ICP-MS in cell and tumors to quantify the targeting drug delivery efficacy. Tumor weight and mice weight were investigated to study the targeting antitumor efficacy of nanogel system.
resultsThe results revealed that using AuCOOH@FACS nanogel as delivery vehicles, drugs could be targeting delivery to tumor site, the intracellular uptake is enhanced to a greater extent, and significant antitumor efficacy is fold increase compared with free drug administration group, without noticeable system cytotoxicity.
conclusionsThis system offers an efficient approach to cancer therapy and holds significant potential to improve the treatment of cancer in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.